An analysis of the central vasomotor effects of monoamine oxidase inhibitor, modaline sulphate.
D000818:Animals; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D002217:Carbachol / Q000494:pharmacology; D002339:Carotid Arteries; D002552:Cerebral Ventricles; D004285:Dogs; D005260:Female; D006426:Hemicholinium 3 / Q000494:pharmacology; D007267:Injections; D008297:Male; D010643:Phenoxybenzamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology*; D013268:Stimulation, Chemical; D013618:Tachyphylaxis; D013747:Tetrabenazine / Q000494:pharmacology; D014159:Transducers; D014630:Vagus Nerve / Q000502:physiology; D014666:Vasomotor System / Q000187:drug effects*
D011719:Pyrazines; D010643:Phenoxybenzamine; D006426:Hemicholinium 3; D001285:Atropine; D002217:Carbachol; D011433:Propranolol; D013747:Tetrabenazine